Plain language summary of prostate-specific antigen (PSA) response to darolutamide in metastatic hormone-sensitive prostate cancer and its effect on treatment outcomes in the ARASENS trial
This Plain Language Summary of Publication article (PLSP) from Future Oncology, presents a post-hoc analysis of the ARASENS trial, which examined how prostate-specific antigen (PSA) response influenced treatment outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). The study included 1,305 patients and found that adding darolutamide to androgen deprivation therapy (ADT) and docetaxel improved survival and reduced the risk of death by 32.5%. The rate of adverse events was similar between those receiving darolutamide and those receiving a placebo with ADT and docetaxel.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study’ and was published in European Urology.
Visit Elsevier using the link to read the original article.